The Gut–Brain Axis in Childhood Developmental Disorders
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Primary gastrointestinal pathology may play an important role in the inception and clinical expression of some childhood developmental disorders, including autism. During the past 4 years, it has been my privilege to work with one of the finest pediatric gastroenterology teams in the world, headed by John Walker-Smith, on an innovative and challenging investigation of gastrointestinal pathology in children with autism. We believe that this work will provide new and important insights into the pathogenesis of this devastating condition. Although the primary causes of autism may be diverse, clues to the possible origin of the disease may be found in the history and clinical investigation of affected children. This talk focuses on the significance of gastrointestinal symptoms in autistic children, in particular, a subset of children for whom the clinical course is characterized by regression after at least 12 to 15 months of normal development. In addition to frequent gastrointestinal symptoms, children with autism often manifest complex biochemical, metabolic, and immunologic abnormalities that a primary genetic cause cannot readily account for. The gut–brain axis is central to certain encephalopathies of extracranial origin, hepatic encephalopathy being the best characterized. Certain commonalties between the clinical characteristics of hepatic encephalopathy and an increasingly common autistic phenotype (developmental regression in a previously normal child accompanied by immune-mediated gastrointestinal pathology) have led to the hypothesis that an analogous mechanism of toxic encephalopathy may exist in patients with liver failure and some children with autism. Aberrations in opioid biochemistry are common to these two conditions, and evidence suggests that opioid peptides may be among the central mediators of the respective syndromes. Generating biologically plausible and testable hypotheses in this area may help to identify new treatment options in encephalopathies of extracranial origin. Interest is growing in the role of the gut in childhood developmental disorders, principally autism. Some of the earliest commentators on pathobiologic mechanisms in autism made the observation that gastrointestinal symptoms are common in children with developmental disorders. Dohan wrote: “K Soddy (University College Hospital, London) wrote me that he noted that recurrent gastrointestinal upsets were a constant feature of autistic children and that, among other symptoms, the deteriorating autistic child often has acute diarrhea” (1). These observations have been iterated in parental accounts (2), but largely ignored by the medical profession (Bauman M, personal communication). More recently, in a systematic analysis of an unselected population of 385 children on the autistic spectrum, clinically significant gastrointestinal symptoms occurred in 46% compared with 10% of 97 developmentally normal pediatric controls (odds ratio, 7.4; confidence intervals, 3.60–15.65;P < 0.0001) (3). We investigated gastrointestinal symptoms in more than 150 autistic children and reported out initial experience (4,5). In this cohort, developmental regression and loss of acquired skills, sometimes occurring precipitously over a period of days to weeks, followed a period of initial normal development; in short, the children became encephalopathic. Longstanding intestinal symptoms, including chronic constipation with overflow, and provocation of both gastrointestinal and behavioral symptoms by certain foods, are typical of this group of children and have been described by others (6). However, even among some pediatric gastroenterologists, the perception remains that such symptoms are to be expected in children with developmental disorders, reflecting effect rather than possible cause. In the absence of thorough investigation, the basis for this presumption is unclear. It is essential, ab initio, to ask whether these symptoms reflect underlying pathology of the gastrointestinal tract. In 1972, Walker-Smith and Andrews (7) reported low concentrations of α-1-antitrypsin in children with classic autism, a finding indicative of intestinal protein loss. We have subsequently reported increased fecal excretion of calprotectin in children with autistic regression associated with enterocolitis. There was a high degree of correlation between fecal calprotectin and neutrophil infiltration of the colonic mucosa (8). Calprotectin is a stable neutrophil product, and its presence in feces is an established marker of active inflammation in inflammatory bowel disease. Intestinal permeability, as measured by urinary excretion of metabolically inert sugars after oral dosing, is a surrogate marker of mucosal integrity and is increased in the presence of intestinal inflammation, as in Crohn disease (9) and celiac disease (10). D'Eufemia et al. (11) reported that approximately half of a cohort of autistic children without gastrointestinal symptoms had increased in
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wakefield, A., Murch, S., Anthony, A., Linnell, J., Casson, D., Malik, M., Berelowitz, M., Dhillon, A., Thomson, M., Harvey, P., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11096-0 · Cited by 3,006
Self-citationRetractedTibble, J. A., Sigthorsson, G., Bridger, S., Fagerhol, M. K., & Bjarnason, I. (2000) · Gastroenterology · doi:10.1053/gast.2000.8523 · Cited by 759
Short-Term Benefit From Oral Vancomycin Treatment of Regressive-Onset Autism
Sandler, R. H., Finegold, S. M., Bolte, E. R., Buchanan, C. P., Maxwell, A. P., Väisänen, M.-L., Nelson, M. N., & Wexler, H. M. (2000) · Journal of Child Neurology · doi:10.1177/088307380001500701 · Cited by 614 · cited 1×
“(36) noted objective cognitive improvement in autistic children in an open label study of oral vancomycin, an antibiotic that exhibits minimal systemic absorption.”
BackgroundAbnormal intestinal permeability in children with autism
D'Eufemia, P., Celli, M., Finocchiaro, R., Pacifico, L., Viozzi, L., Zaccagnini, M., Cardi, E., & Giardini, O. (1996) · Acta Paediatrica · doi:10.1111/j.1651-2227.1996.tb14220.x · Cited by 416 · cited 1×
“(11) reported that approximately half of a cohort of autistic children without gastrointestinal symptoms had increased intestinal permeability.”
BackgroundBolte, E. R. (1998) · Medical Hypotheses · doi:10.1016/s0306-9877(98)90107-4 · Cited by 213
Cited by
Desbonnet, L., Garrett, L., Clarke, G., Bienenstock, J., & Dinan, T. G. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.03.009 · Cited by 952
“…literature presents compelling evidence for the existence of a ‘‘brain–gut axis” (BGA), and suggests that not only can the brain affect gut function, but that the gut, by both direct and indirect mechanisms, can also induce changes in the CNS (Shanahan, 1999; Wakefield, 2002; Mayer et al., 2006).”
BackgroundThe Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder
Srikantha, P., & Mohajeri, M. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092115 · Cited by 400
“[1,14,15,16,17,18 ,19] Increased permeability of the epithelial barrier in the gut [15,54,55]”
BackgroundIncidence of Gastrointestinal Symptoms in Children With Autism: A Population-Based Study
Ibrahim, S. H., Voigt, R. G., Katusic, S. K., Weaver, A. L., & Barbaresi, W. J. (2009) · PEDIATRICS · doi:10.1542/peds.2008-2933 · Cited by 298
Samsel, A., & Seneff, S. (2013) · Entropy · doi:10.3390/e15041416 · Cited by 293
O'Sullivan, E., Barrett, E., Grenham, S., Fitzgerald, P., Stanton, C., Ross, R., Quigley, E., Cryan, J., & Dinan, T. (2011) · Beneficial Microbes · doi:10.3920/bm2011.0015 · Cited by 92
Metadata
- Authors
- Wakefield, A. J.
- Venue
- Journal of Pediatric Gastroenterology and Nutrition
- Publisher
- Wiley
- Published
- 2002-05
- Volume
- 34
- Pages
- S14-S17
- ISSN
- 0277-2116 (ISSN-L)
- OpenAlex
- W2055750137
- Cited by
- 33
- References
- 5
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Gut–Brain Axis in Childhood Developmental Disorders. https://app.cochat.ai/papers/10.1097/00005176-200205001-00004
- The paper
- Wakefield, A. J. (2002). The Gut–Brain Axis in Childhood Developmental Disorders. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1097/00005176-200205001-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.